Myeloproliferative Neoplasms (MPNs) [Excluding CML]

Primary Myelofibrosis (PMF)

Previously enrolled in HEMMPD0020 or HEMMPD0018

HEMMPD0031 Phase II Luspatercept (ACE-536) in Myeloproliferative Neoplasm-Associated Myelofibrosis & Anemia +/-
PI: Genentech

Progressed / Intolerant on JAK

HEMMPD0030 Phase II Pacritinib in Myeloproliferative Disorders Previously Treated with Ruxolitinib
PI: Gilead

HEMMPD0034 Phase II Avapritinib (BLU-285) KIT Mutation-targeted TKI in Advanced Systemic Mastocytosis
PI: Gilead

CD30-

HEMMPD0027 Phase I BLU-285 in Advanced Systemic Mastocytosis (dysSM)
& Relapsed / Refractory Myeloid Malignancies
PI: Gilead

HEMMPD0029 Phase I DCC-2618 in Advanced Malignancies
PI: Gilead

Aggressive Systemic Mastocytosis/ Mast Cell Leukemia

Chronic Neutrophilic Leukemia (CML) and Atypical Chronic Myeloid Leukemia (CML)

FGFR1 Rearrangement

HEMMPD0022 Phase II Prospective Evaluation of Ruxolitinib Efficacy for CML/aCML Patients with Mutation of CS3FR
PI: Gilead

HEMMPD0028 Phase II INCB05482 in Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
PI: Incyte Corporation

HEMMPD0035 Phase II Ruxolitinib in Idiopathic Hypereosinophilic Syndrome & Primary Eosinophilic Disorders
PI: Gilead

KEY

- Pending
- Open for Enrollment
- Link
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold